Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $443000.0.

  • Century Therapeutics' Change in Accured Expenses fell 8033.73% to $443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year increase of 3259.28%. This contributed to the annual value of $1.6 million for FY2024, which is 31945.21% up from last year.
  • As of Q3 2025, Century Therapeutics' Change in Accured Expenses stood at $443000.0, which was down 8033.73% from $707000.0 recorded in Q2 2025.
  • Century Therapeutics' Change in Accured Expenses' 5-year high stood at $2.9 million during Q3 2023, with a 5-year trough of -$6.5 million in Q1 2025.
  • Its 4-year average for Change in Accured Expenses is -$37666.7, with a median of $707000.0 in 2025.
  • As far as peak fluctuations go, Century Therapeutics' Change in Accured Expenses crashed by 31086.57% in 2023, and later skyrocketed by 39705.88% in 2025.
  • Century Therapeutics' Change in Accured Expenses (Quarter) stood at $1.1 million in 2022, then tumbled by 310.87% to -$2.4 million in 2023, then surged by 221.74% to $2.9 million in 2024, then crashed by 84.76% to $443000.0 in 2025.
  • Its Change in Accured Expenses stands at $443000.0 for Q3 2025, versus $707000.0 for Q2 2025 and -$6.5 million for Q1 2025.